Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
Tel Aviv, Israel / Vancouver, Canada, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD). The latest in-vivo studies examined the effect of MEAI on the natural reward process as it pertains to cocaine addiction.
- The latest in-vivo studies examined the effect of MEAI on the natural reward process as it pertains to cocaine addiction.
- The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel.
- As previously announced (see press release August 24, 2022), Clearmind's proprietary MEAI at a dose of 5mg/kg, demonstrated unique ability to decrease cocaine craving and potentially become the first dedicated cocaine addiction treatment.
- The empirical data show that MEAI is a potential treatment for cocaine addiction, in particular, and SUD, in general.